Novartis, Inc.     04/20/17-06/30/19   
LCZ696 Restore the Peri-Infarct Region in Advanced Heart Failure
The major goal is to evaluate the mechanism of action of LCZ696 in repairing the injured myocardium in advanced heart failure
Role: Principal Investigator

NIH/SBIR    2 R44 EB019239-02    9/1/14-11/30/17
Tracking cardiac engraftment and viability of MiPSCs by MRI
The major goal is to develop a non-invasive and efficient technology for monitoring transplanted cells in the body using MRI.
Role: Principal Investigator

NIH/NHLBI/CCTRN    7/1/16-12/31/17 
The SENECA Trial: A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells by transendocardial injection to cancer survivors with left ventricular dysfunction secondary to anthracycline-induced cardiomyopathy.
Role: Principal Investigator

NIH/NHLBI/CCTRN    12/1/15-2/28/19
The CONCERT-HF Trial: Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells and c-kit+ cardiac stem cells both alone and in combination, compared to placebo as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.
Role: Principal Investigator

NIH/NHLBI/CCTRN    6/1/13-3/31/17   
The PACE Trial: Bone Marrow Derived ALDH Bright Cells in Intermittent Claudication
The purpose of this study is to find out if aldehyde dehydrogenase bright cells taken from a patient's bone marrow can be placed safely, via intramuscular injections, into their affected calf and lower thigh muscles and improve blood flow and/or peak walking time in patients experiencing pain associated with blocked blood vessels in the leg.
Role: Principal Investigator

NIH/NHLBI    5UM1 HL113456-02    4/1/12 - 3/31/19
Cell Characterization and Imaging for Regenerative therapies in Ischemic Diseases – Cardiovascular Cell Therapy Research Network
The major goal of this project is to contribute to the clinical effort of the Cardiovascular Cell Therapy Research Network (CCTRN) through our innovative approaches to in vivo imaging and induced pluripotent stem cell derived cardiomyocytes.
Role: Principal Investigator

NIH/NHLBI    1 K24 HL130553      4/01/16-03/31/21
Patient Oriented Research in Cardiovascular Regeneration
The major goal is to perform career development activities and mentor trainees in the design and conduct of novel stem cell therapy clinical trials.
Role: Principal Investigator

Teva Pharmaceutical Industries        1/1/14-8/31/18
A Double-blind, Randomized, Sham-procedure-controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells in Patients With Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Non-ischemic Etiology
The purpose of this study is to evaluate the efficacy and safety of allogeneic mesenchymal precursor cells for the treatment of chronic heart failure.
Role: Principal Investigator

General Electric Company    AW623514    9/1/15-11/30/17   
Clinical Trial of Comprehensive Characterization of the Peri-Infarct Region employing ASL & T1 Mapping
This clinical research study will assess the role of T1-map, manganese-enhanced MRI, and ASL in assessing the peri-infarct region in patients with ischemic cardiomyopathy.
Role: Principal Investigator

NIH/NHLBI    1R01 HL127039-0    9/1/15-7/31/19   
Coronary Magnetic Resonance Angiography
The major goal of this project is to develop and evaluate MRI methods for noninvasive imaging of the coronary arteries.
Role: Investigator    PI: Dwight Nishimura

CIRM - Disease Team Therapy Development Award    DR2A-05394    4/1/13-3/31/18
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure
The goal of this proposal is to prepare for a Phase I clinical trial to determine the safety of human embryonic stem cell derived cardiomyocytes for patients with end-stage heart failure.
    Role: Investigator            PI: Joseph W